Drug intelligence / Profile preview

DX-107

Development stage: Preclinical
Lead developer: Delonix Bioworks
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DX-107 is a preclinical-stage vaccine candidate being developed by Delonix Bioworks for the prevention of *Neisseria gonorrhoeae* infection. The vaccine is built on the proprietary OMV Plus® platform technology, which utilizes genetically engineered outer membrane vesicles (OMVs) to present bacterial surface antigens. These engineered OMVs are designed to possess intrinsic adjuvant properties, which enhance the immunogenicity of the presented antigens without the need for external adjuvants. DX-107 aims to induce protective immunity against gonorrhea, addressing a critical unmet medical need caused by the rise of antimicrobial-resistant strains of *N. gonorrhoeae*.

Other names: DX-107 OMV Plus vaccineDX107 OMV Plus vaccineDX 107 OMV Plus vaccine

Beyond the preview

Go deeper on DX-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DX-107.

Explore the full profile